Glaxosmithkline S.a.e. · EGX:BIOC

Glaxosmithkline S.a.e — GlaxoSmithKline Pharmaceuticals — Q4 FY25 Earnings Presentation

13 slides from Glaxosmithkline S.a.e's earnings presentation, May 13, 2025

  1. Slide 1: Cover letter to stock exchanges: Presentation of Analyst / Institutional Investor Meetings

    GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 13th May 2025 To, BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchang

  2. Slide 2: GlaxoSmithKline Pharmaceuticals Limited

    GlaxoSmithKline Pharmaceuticals Limited 13th May, 2025 gsk.com

  3. Slide 3: Committed to India in our second century of operations

    Committed to India in our second century of operations… Bringing together science, technology and talent to deliver impact #AheadTogether 2

  4. Slide 4: Priority brands performance driving competitive edge in General Medicines

    Priority brands performance driving competitive edge in General Medicines Uniting science, Enhanced access Strengthening Maximize potential technology and talent and sharp focus market leadership in the SITT Market +0.5% 103 1.2x 120 1.1x 101 ~1.8x 137 Val growth Unit EI Vol growth Unit EI Vol growt

  5. Slide 5: Key brands of General Medicines and Pediatric Vaccines deliver competitive performance in Q4

    Key brands of General Medicines and Pediatric Vaccines deliver competitive external performance in Q4 General Medicines key brands deliver Improving our SoV and Elevating customer competitive performance experience through digital innovation Brand Unit EI Augmentin 103 Calpol 101 400K+ Ceftum* 120 U

  6. Slide 6: GSK leading the Vaccines market with ~21.2% market share

    GSK leading the Vaccines market with ~21.2% market share Year 1 In clinic Promotion and Rank #1 /#2 HCP engagement Maintain Leadership Year 2 Expanding the market Ahead of market through HCO engagement & Patient Awareness (Collaboration with IAP to educated Pediatricians) Havrix & Varilrix EI>100 Ma

  7. Slide 7: Building equity in respiratory segment through science-led differentiation

    Building equity in respiratory segment by redefining goals for clinical outcomes and through science-led differentiation 2250+ 5.9% EI 137 Severe asthma patients benefitted Val MS in cluttered SITT class Unit EI #1 Accelerate Initiation of Nucala #1 Differentiation vs other SITTs • Accelerate initia

  8. Slide 8: Shingrix update across 'must wins'

    Shingrix update across ‘must wins’ Improve risk & severity perception Improve strength of HCP Improve ease of inoculation for for Shingles recommendation patients Digital screens pilot in 10 clinics – scale up plan for 300 by July’ 2025 Vaccination card roll Indian consensus out to all clinics & gui

  9. Slide 9: Accolades & recognitions

    Accolades & recognitions Great Place to work - Certification Annual OPPI Awards 2024-25 EHS excellence Award 2024-25 received by Nashik manufacturing unit Winner – Sales Force Excellence Award  GSK Worli received, Adult immunization clinic set up at Fortis Leesman+ Escorts, Heart institute, Delhi –

  10. Slide 10: Financial Highlights: FY Apr'24-Mar'25 (Standalone)

    Financial Highlights : FY Apr’24-Mar’25 (Standalone) Revenue EBITDA PAT (before exceptional) ₹3723cr ₹1169cr ₹915cr Growth +9% Growth +30% Growth+32% Margin: 31% Margin: 25% Revenue growth +9% EBITDA margin +500 bps (YoY) PAT +440 bps (YoY)  General Medicine key Pharma brands volume  PAT stepped u

  11. Slide 11: Consistent improved Profitability and Return Ratios (Standalone)

    Consistent improved Profitability and Return Ratios (Standalone) Gross Margin EBITDA Employee Cost to Sales 31.4% 62.9% 26.4% 19.1% 18.7% 18.4% 61.9% 24.8% 23.6% 15.7% 60.7% 59.4% FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 ROCE Return on Net Worth Market Cap (Rs. Cr) 63.8% 46.9% 48,

  12. Slide 12: Financial Highlights: Q4 FY25 (Standalone)

    Financial Highlights : Q4 FY25 (Standalone) Revenue EBITDA PAT (before exceptional) ₹966cr ₹331cr Growth +30% ₹260cr Growth +6% Margin: 34% Growth+36% Margin: 27% Revenue growth +6% EBITDA margin +620 bps (YoY) PAT +590 bps (YoY)  General Medicine key Pharma brands volume growth +5%; lower than exp

  13. Slide 13: Thank you!

    gsk.com Thank you!

GlaxoSmithKline Pharmaceuticals — Q4 FY25 Earnings Presentation on 6ix